Butyrate inhibits type 2 inflammation in eosinophilic chronic rhinosinusitis
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.149967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Masatomo Toyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0215, Japan; Departmen…. Hauptthemen laut MEDLINE: Butyrates, Cytokines, Receptors, Cell Surface, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Butyrate and other Short-chain fatty acids (SCFAs) are microbial metabolites from Bacteroides and Clostridium species that may suppress type 2 inflammation. However, the mechanisms of SCFAs in the nasal sinuses are not fully understood. We aimed to clarify the in vitro and in vivo roles of SCFAs in eosinophilic chronic rhinosinusitis (ECRS) pathophysiology. We investigated whether SCFAs induced changes in type 2 cytokines, IgE, and apoptosis and the roles of GPR41, GPR43, and histone deacetylase. Analysis of the control subjects demonstrated that butyrate of SCFAs effectively inhibited type 2 cytokine production in PBMCs, ILC2s, and CD4+ T cells and IgE production in CD19+ B cells. In annexin V analysis, butyrate also induced late apoptosis of PBMCs. The butyrate-induced inhibition of type 2 cytokines appeared involved in histone deacetylase inhibition but not in GPR41 or GPR43. In an analysis of ECRS in humans, butyrate inhibited type 2 cytokine production in PBMCs and nasal polyp-derived cells. The butyrate concentration in nasal lavage fluid was significantly decreased in ECRS patients compared to controls and non-ECRS patients. Our findings confirm that butyrate can inhibit type 2 inflammation and may be a potential therapeutic target for ECRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0215, Japan; Department of Otorhinolaryngology and Head and Neck Surgery, Shiga University o…
- Department of Otorhinolaryngology and Head and Neck Surgery, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0215, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0215, Japan. Electronic address: suzuki@med.u-ryukyu.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Toyama, M., Kouzaki, H., Shimizu, T., Hirakawa, H., & Suzuki, M. (2024). Butyrate inhibits type 2 inflammation in eosinophilic chronic rhinosinusitis. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.149967
Vancouver
Toyama M, Kouzaki H, Shimizu T, Hirakawa H, Suzuki M. Butyrate inhibits type 2 inflammation in eosinophilic chronic rhinosinusitis. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.149967
BibTeX
@article{Toyama2024,
author = {Toyama, Masatomo and Kouzaki, Hideaki and Shimizu, Takeshi and Hirakawa, Hitoshi and Suzuki, Mikio},
title = {Butyrate inhibits type 2 inflammation in eosinophilic chronic rhinosinusitis},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.149967}
}
EUVIMED